The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination therapy might change that.

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

A preliminary study on popular weight loss drugs finds participants shed more weight on Zepbound than on Novo Nordisk’s Wegovy, Zepbound maker Eli Lilly said.

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

Eli LillyDemand for weight-loss drugs in India has shot up.And rivals Novo Nordisk and Eli Lilly are battling for market ...

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.

India's Rs 628-crore anti-obesity market sees heightened competition as Wegovy and Mounjaro post strong sales amid rising ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...